Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.

被引：0
|
作者：
Niu, Nan
Cao, Shuo
Chen, Guanglei
Xue, Jinqi
Zhang, Yu
Xu, Yongqing
Yin, Jianqiao
Liu, Chao
Jiang, Xiaofan
Tang, Meiyue
Xu, Qianshi
Jia, Mingxuan
Zhang, Xu
Zhang, Zhenyong
Li, Huajun
Li, Ailin
Liu, Caigang
机构：
[1] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China
[2] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12604
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [2] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [3] BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Ito, Yoshinori
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Piccart-Gebhart, Martine J.
    Hortobagyi, Gabriel N.
    Rugo, Hope S.
    Gnant, Michael
    Campone, Mario
    Sahmoud, Tarek
    Pritchard, Kathleen I.
    Burris, Howard A.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
    Xu, Binghe
    Zhang, Qingyuan
    Zhang, Pin
    Hu, Xichun
    Li, Wei
    Tong, Zhongsheng
    Sun, Tao
    Teng, Yuee
    Wu, Xinhong
    Ouyang, Quchang
    Yan, Xi
    Cheng, Jing
    Liu, Qiang
    Feng, Jifeng
    Wang, Xiaojia
    Yin, Yongmei
    Shi, Yanxia
    Pan, Yueyin
    Wang, Yongsheng
    Xie, Weimin
    Yan, Min
    Liu, Yunjiang
    Yan, Ping
    Wu, Fei
    Zhu, Xiaoyu
    Zou, Jianjun
    NATURE MEDICINE, 2021, 27 (11) : 1904 - +
  • [5] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
    Binghe Xu
    Qingyuan Zhang
    Pin Zhang
    Xichun Hu
    Wei Li
    Zhongsheng Tong
    Tao Sun
    Yuee Teng
    Xinhong Wu
    Quchang Ouyang
    Xi Yan
    Jing Cheng
    Qiang Liu
    Jifeng Feng
    Xiaojia Wang
    Yongmei Yin
    Yanxia Shi
    Yueyin Pan
    Yongsheng Wang
    Weimin Xie
    Min Yan
    Yunjiang Liu
    Ping Yan
    Fei Wu
    Xiaoyu Zhu
    Jianjun Zou
    Nature Medicine, 2021, 27 : 1904 - 1909
  • [6] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [7] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [9] Methods for selection of neoadjuvant treatment with chemotherapy for patients with hormone receptor-positive and HER2-negative with early breast cancer.
    Gasol Cudos, Ariadna
    Morales Murillo, Serafin
    Tuset Der-abrain, Noemi
    Arbones Cid, Laura
    Morera Morillo, Ester
    Vilardell, Felip
    Sanchez Guzman, Douglas
    Canosa Morales, Carles
    Mele Olive, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
12345